/publications/issue/2013/August2013/RX-Product-News-0813

Rx Product News

Author:




Qsymia
Marketed by:
Vivus, Inc
Indication: Qsymia (phentermine and topiramate extended-release) is FDA approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 or greater or a BMI of 27 or greater with a weight-related comorbidity. Vivus, Inc, has announced the availability of Qsymia capsules in approximately 8000 certified retail pharmacies nationwide.
Dosage Form: Capsules (phentermine/topiramate extended-release): 3.75 mg/23 mg, 7.5 mg/46 mg, 11.25 mg/69 mg, and 15 mg/92 mg
For More Information: www.qsymia.com






Brisdelle
Marketed by:
Noven Pharmaceuticals, Inc
Indication: The FDA has approved Brisdelle (paroxetine) for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. Prior to this approval, hormone therapy was the only FDA-approved treatment for VMS. The low dose of paroxetine in Brisdelle has not been studied in psychiatric conditions; therefore, Brisdelle is not approved for psychiatric use. The recommended dosage is 7.5 mg once daily at bedtime.
Dosage Form: Capsules: 7.5 mg
For More Information: www.brisdelle.com




Nesina
Marketed by:
Takeda Pharmaceutical Company Limited
Indication: Nesina (alogliptin) was approved by the FDA this year as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Nesina is not for treatment of type 1 diabetes or diabetic ketoacidosis. The recommended dose in patients with normal renal function or mild renal impairment is 25 mg once daily.
Dosage Form: Tablets: 6.25, 12.5, and 25 mg
For More Information: www.takedadiabetesadvantage.com




Zubsolv
Marketed by:
Orexo US, Inc
Indication: The FDA has approved Zubsolv (buprenorphine and naloxone) sublingual tablets for the maintenance treatment of opioid dependence. The drug is indicated for use as part of a complete treatment plan that includes counseling and psychosocial support. The recommended daily dose for maintenance treatment is 11.4 mg buprenorphine and 2.8 mg naloxone. Patients should be advised not to cut, chew, or swallow the tablets.
Dosage Form: Sublingual tablets (buprenorphine/naloxone): 1.4 mg/0.36 mg and 5.7 mg/1.4 mg
For More Information: www.orexo.com/en/Products/Zubsolv_Treatment_of_opioid_dependence